Form 4: Merck Director Risa J. Lavizzo-Mourey Reports Acquisition of Phantom Stock Units

Merck & Co., Inc. Director Risa J. Lavizzo-Mourey reported the acquisition of 2,863.0921 phantom stock units as part of her compensation plan, increasing her total beneficial ownership of phantom stock to 15,367.349 units.

Summary

• Risa J. Lavizzo-Mourey, a Director at Merck & Co., Inc. (MRK), reported changes in her beneficial ownership of company securities.
• On May 30, 2025, Ms. Lavizzo-Mourey acquired 2,863.0921 phantom stock units at a price of $76.84 per unit.
• Following this transaction, her total beneficial ownership of phantom stock units increased to 15,367.349 units.
• These phantom stock units are designed to be settled 100% in cash upon her termination of service, in accordance with a distribution schedule elected under the Plan for Deferred Payment of Directors' Compensation.
• Her holdings also include 1,000 shares of Common Stock held directly.
• The reported phantom stock holdings include units acquired through dividend reinvestment transactions.

Sentiment

Score: 7

Explanation: The document reports a routine compensation-related acquisition of phantom stock units by a director, which is a neutral to slightly positive event as it aligns the director's interests with the company's long-term performance. It does not indicate any significant positive or negative operational or financial news.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of the company, as these units are part of a compensation plan.
• The transaction reflects a routine compensation event for a director, indicating stability in corporate governance practices.

Future Outlook

The acquired phantom stock units are scheduled to be settled 100% in cash upon the reporting person's termination of service, in accordance with a pre-elected distribution schedule under the company's deferred compensation plan for directors.

Management Comments

• The phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

Industry Context

This Form 4 filing details a routine insider transaction related to director compensation. The use of phantom stock units is a common practice in large corporations, particularly in the pharmaceutical industry, to align the interests of directors with long-term shareholder value without issuing physical shares immediately.

Comparison to Industry Standards

• The use of phantom stock units as a component of director compensation is a common and accepted practice across various industries, including pharmaceuticals, aligning director incentives with company performance.
• Many large-cap pharmaceutical companies, such as Pfizer, Johnson & Johnson, and Bristol Myers Squibb, utilize similar deferred compensation plans for their non-employee directors, often involving equity-linked instruments like phantom stock or restricted stock units, to encourage long-term commitment and ownership perspective.

Corporate Governance

Related Party Transactions

• The acquisition of phantom stock units by a director as part of their compensation plan constitutes a routine related-party transaction, governed by the company's established compensation policies.

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic decision-making.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Phantom stock units will be settled in cash upon the reporting person's termination of service, as per the elected distribution schedule.

Key Dates

Recommendation

Keywords

Merck & Co. Inc., MRK, SEC Form 4, insider transaction, beneficial ownership, phantom stock, director compensation, Risa J. Lavizzo-Mourey, corporate governance